OINDPnews


Aptar Pharma banner

Medical

Positive Phase II results for Relovair dry powder inhaler

GlaxoSmithKline has announced that the Relovair fluticasone furoate/vilanterol trifenatate DPI it is developing with Theravance showed good results in a Phase II study involving 60 COPD patients. Studies of the component drugs for asthma also demonstrated efficacy and safety, according to GSK. Phase III studies for both COPD and asthma are underway. Read the … [Read more...] about Positive Phase II results for Relovair dry powder inhaler

NHLBI study shows tiotropium/ICS combo effective for asthma

A study by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) shows that a combination of tiotropium bromide with a low dose of inhaled corticosteroid (ICS) provides better asthma control than doubling the dose of ICS and is as effective as a salmeterol/ICS combination. Patients taking the tiotropium combination gained … [Read more...] about NHLBI study shows tiotropium/ICS combo effective for asthma

Phase III data shows Onbrez better for COPD than salmeterol

Novartis has announced that its Phase III INSIST study shows that its once-daily Onbrez Breezhaler indacaterol DPI produces better bronchodilation in COPD patients than does twice-daily salmeterol. Onbrez also reduced the need for rescue medication, according to the data presented. The FDA has requested additional clinical data from Novartis for consideration of … [Read more...] about Phase III data shows Onbrez better for COPD than salmeterol

Boston Scientific buys Asthmatx, hopes to expand use of bronchial thermoplasty

Boston Scientific has acquired Asthmatx, the developer of a bronchial thermoplasty procedure marketed as an alternative to inhaled medications for the treatment of severe asthma for an upfront payment of $193.5 million and future payments of up to $250 million. The Alair Bronchial Thermoplasty System, which was approved by the FDA in April 2010, uses heat to … [Read more...] about Boston Scientific buys Asthmatx, hopes to expand use of bronchial thermoplasty

MAP announces Levadex trial results

A PD study has shown no statistically significant difference in pulmonary artery pressure effects of Levadex inhaled dihydroergotamine (DHE) compared to placebo, according to MAP Pharmaceutical. The inhaled formulation had a smaller effect on pulmonary artery pressure than IV DHE. MAP has said that it intends to submit an NDA for Levadex for the treatment of … [Read more...] about MAP announces Levadex trial results